Follow the Money to Medical Devices & Diagnostics
Spotlight on CVRx, Inc.
Follow the Money to Medical Device & Diagnostic Opportunities highlights a newly funded medical device or diagnostic company. This includes important insights into the featured company’s product pipeline, manufacturing and business relationships, and likely sourcing opportunities.
CVRx is a U.S. private company that develops proprietary technologies for the treatment of high blood pressure and heart failure. It raised $113 million in a completion of a mixed financing round, which included $93 million in equity financing and a $20 million debt facility, as reported in the PharmSource Lead Sheet on August 11, 2016.
- CVRx was founded in 2001
- Corporate Headquarters: Minneapolis, MN
- CVRx plans to use the proceeds to support the following clinical trial:
Device: Barostim Neo™
Development Phase: Pivotal studies
Medical Specialty: Cardiovascular/Vascular
Purpose: Device – Therapeutic/Interventional
Type: Implant – Other; Electrode/Stimulator
Description: An invasive implant that activates the baroreceptors in the carotid artery for the treatment of hypertension and heart failure
US – PMA planned
EU – CE Mark approval
US – Other
Classification: US Class III
- June 2016: $46.5 million in a completed venture capital investment
- September 2014: $15 million in a completed private debt placement
- October 2013: $12 million in a completed venture capital investment
- July 2013: $29.6 million in a completed venture capital investment
Medical Device & Diagnostics Pipeline1
|Product Candidate||Indication||Medical Specialty||Purpose||Type|
|Cardiovascular/Vascular||Device – Therapeutic/Interventional||Implant – Other;
Regulatory Approvals and Clearances
|Product Candidate||Region||Approval/Clearance||Year of Approval or Clearance|
|Barostim neo||USA||Expedited Access Pathway (EAP)||2015|
|Barostim neo||EU||CE Mark||2014|
|Barostim neo||EU||CE Mark (MR Conditional Expanded labeling)||2014|
|Barostim neo||USA||Humanitarian Device Exemption (HDE)||2014|
1Source: PharmSource Lead Sheet
|CVRx, Inc.||Key Officers|
|9201 West Broadway Avenue, Suite 650||Nadim Yared, President & CEO|
|Minneapolis, MN, 55445 USA||John Brintnall, CFO|
|Phone: +1-763-416-2840||Dead Bruhn-Ding, VP, Regulatory Affairs & QA|
|Fax: +1-763-416-2841||Robert Kieval, Chief Development Officer|
|Web: www.cvrx.com||Joseph DuPay, VP, Research, Development & Operations|
Follow the Money to Medical Device & Diagnostic Opportunities – Spotlight on Avita Medical Ltd.
Follow the Money to Medical Devices & Diagnostics – Spotlight on Mainstay Medical International plc.
Follow the Money to Medical Device & Diagnostic Opportunities – Spotlight on EndoStim, Inc.